Expert Kidney Disease & Transplantation Care in Shanghai
The Department of Nephrology at Renji Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of China's most distinguished nephrology centers, with a national reputation for excellence in the diagnosis and management of glomerulonephritis, lupus nephritis, IgA nephropathy, diabetic kidney disease, hereditary kidney diseases, acute kidney injury, chronic kidney disease, and kidney transplantation. The department combines outstanding clinical expertise with a world-class research program and a fully integrated multidisciplinary approach, offering international patients access to some of China's most eminent nephrologists and the latest evidence-based treatments for complex kidney diseases.
For international patients with lupus nephritis, IgA nephropathy, FSGS, ANCA vasculitis, diabetic kidney disease, or end-stage renal disease requiring kidney transplantation — Renji Hospital's nephrology department offers an unparalleled combination of clinical expertise, research leadership, and transplantation capability. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at Renji Hospital.
About the Department
Renji Hospital's nephrology department is a national key clinical specialty operating dedicated nephrology inpatient wards, a comprehensive outpatient nephrology clinic, a kidney biopsy service with expert renal pathology, a hemodialysis center, a peritoneal dialysis program, a kidney transplantation unit, and subspecialty clinics for lupus nephritis, IgA nephropathy, diabetic kidney disease, and hereditary nephropathies. The department works in close collaboration with rheumatology, urology, transplant surgery, pathology, and genetics through a fully integrated multidisciplinary team.
Faculty members publish regularly in leading nephrology journals including Journal of the American Society of Nephrology, Kidney International, American Journal of Kidney Diseases, Clinical Journal of the American Society of Nephrology, and Nephrology Dialysis Transplantation.
Conditions Treated
Glomerular Diseases
- IgA Nephropathy (IgAN) — ACE inhibitors/ARBs for proteinuria reduction; corticosteroids for high-risk IgAN; sparsentan (dual endothelin-angiotensin receptor antagonist); targeted-release budesonide (Nefecon/Kinpeygo); iptacopan (complement factor B inhibitor); atrasentan; zigakibart; SGLT2 inhibitors (dapagliflozin, empagliflozin) for CKD progression reduction
- Focal Segmental Glomerulosclerosis (FSGS) — Corticosteroids; calcineurin inhibitors (cyclosporine, tacrolimus); mycophenolate mofetil; sparsentan for primary FSGS; genetic testing for hereditary FSGS (NPHS1, NPHS2, INF2, TRPC6)
- Membranous Nephropathy (MN) — PLA2R antibody testing; rituximab for PLA2R-positive MN (MENTOR trial); calcineurin inhibitors; obinutuzumab for refractory MN; belimumab combinations
- Minimal Change Disease (MCD) — Corticosteroids; cyclophosphamide for frequently relapsing MCD; rituximab; tacrolimus
- Membranoproliferative GN & C3 Glomerulopathy — Complement pathway inhibitors; iptacopan; pegcetacoplan; eculizumab for complement-mediated MPGN
- Anti-GBM Disease — Plasmapheresis + cyclophosphamide + corticosteroids; emergency dialysis
Lupus Nephritis
Renji Hospital's lupus nephritis program is one of China's most experienced, closely integrated with the rheumatology department's world-class lupus center:
- Class III/IV Lupus Nephritis — MMF or cyclophosphamide + corticosteroids; voclosporin + MMF + belimumab (triple therapy — AURORA 1 trial); obinutuzumab for refractory LN
- Class V (Membranous) Lupus Nephritis — Tacrolimus + MMF; voclosporin; belimumab
- Refractory Lupus Nephritis — Rituximab; obinutuzumab; CAR-T cell therapy (investigational)
- Lupus Nephritis in Pregnancy — Hydroxychloroquine; azathioprine; tacrolimus; low-dose aspirin; LMWH for APS
ANCA-Associated Vasculitis (Renal)
- Rapidly Progressive GN (RPGN) — Rituximab + pulse methylprednisolone for induction; plasmapheresis for severe renal failure or pulmonary hemorrhage; avacopan for steroid-sparing
- Maintenance Therapy — Rituximab maintenance; azathioprine; mycophenolate mofetil
- Renal Recovery — Dialysis support during acute phase; renal recovery monitoring
Diabetic Kidney Disease (DKD)
- Early DKD — Intensive glycemic control; ACE inhibitors/ARBs; SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) for renoprotection; finerenone (non-steroidal MRA) for DKD with albuminuria; GLP-1 receptor agonists (semaglutide) for cardiorenal protection
- Advanced DKD — CKD management; preparation for renal replacement therapy; kidney transplantation evaluation
- Diabetic Nephropathy Biopsy — Kidney biopsy for atypical presentations; pathological classification
Hereditary Kidney Diseases
- Alport Syndrome — COL4A3/COL4A4/COL4A5 mutation testing; ACE inhibitors; sparsentan; lademirsen in trials; kidney transplantation planning
- ADPKD — PKD1/PKD2 testing; tolvaptan for rapidly progressive ADPKD; blood pressure control; pain management; kidney transplantation
- Primary Hyperoxaluria — Lumasiran (RNAi) for PH1; nedosiran; combined liver-kidney transplantation
- Fabry Disease — Enzyme replacement therapy; migalastat for amenable mutations; kidney transplantation
- Complement-Mediated Diseases — aHUS: eculizumab, ravulizumab, iptacopan; C3G: iptacopan, pegcetacoplan
Acute Kidney Injury (AKI)
- AKI in Critically Ill Patients — Fluid management; CRRT for severe AKI; underlying cause treatment; AKI-to-CKD transition prevention
- Contrast-Induced AKI — Prevention protocols; hydration; N-acetylcysteine
- Cardiorenal Syndrome — Diuretic optimization; ultrafiltration; tolvaptan
Chronic Kidney Disease (CKD)
- CKD Progression Slowing — SGLT2 inhibitors; finerenone; ACE inhibitors/ARBs; blood pressure control; dietary protein restriction
- CKD Complications — Anemia (ESAs, roxadustat, daprodustat); mineral bone disease (phosphate binders, active vitamin D, cinacalcet, etelcalcetide); metabolic acidosis; hyperkalemia (patiromer, sodium zirconium cyclosilicate)
- CKD-Associated Cardiovascular Risk — Statin therapy; aspirin; GLP-1 agonists; SGLT2 inhibitors
Kidney Transplantation Program
Renji Hospital's kidney transplantation program is one of the most experienced in Shanghai, performing living and deceased donor kidney transplantation with excellent long-term outcomes:
Pre-Transplant Evaluation
- Comprehensive recipient evaluation: cardiac, vascular, infectious disease, and immunological workup
- HLA typing and panel reactive antibody (PRA) testing
- Crossmatch testing for living donor transplantation
- Desensitization protocols for highly sensitized recipients (plasmapheresis, IVIG, rituximab)
- Living donor evaluation: medical, surgical, immunological, and psychosocial assessment
Transplant Surgery
- Deceased Donor Kidney Transplantation — Standard and expanded criteria donors; machine perfusion for marginal kidneys; dual kidney transplantation for marginal donors
- Living Donor Kidney Transplantation — Laparoscopic donor nephrectomy; ABO-incompatible transplantation with desensitization; paired kidney exchange
- Simultaneous Kidney-Pancreas Transplantation — For type 1 diabetics with ESRD
- Kidney Re-Transplantation — For failed prior transplants; highly sensitized recipients
Post-Transplant Management
- Immunosuppression — Tacrolimus + mycophenolate mofetil + prednisolone; belatacept for CNI-intolerant recipients; mTOR inhibitors for CNI minimization
- Rejection Treatment — Pulse steroids for acute cellular rejection; plasmapheresis + IVIG + rituximab for antibody-mediated rejection; eculizumab for severe AMR
- Infection Prophylaxis — CMV prophylaxis (valganciclovir); PCP prophylaxis (trimethoprim-sulfamethoxazole); antifungal prophylaxis
- BK Virus Nephropathy — Immunosuppression reduction; IVIG; leflunomide; cidofovir
- Chronic Allograft Nephropathy — Immunosuppression optimization; CNI minimization; mTOR inhibitor conversion
- Post-Transplant Malignancy — PTLD: rituximab; immunosuppression reduction; skin cancer surveillance
Dialysis Programs
- Hemodialysis (HD) — In-center hemodialysis; high-flux dialysis; hemodiafiltration (HDF); vascular access management (AVF, AVG, tunneled catheter)
- Peritoneal Dialysis (PD) — CAPD and APD; PD catheter insertion; adequacy monitoring; peritonitis management; home PD training
- Urgent-Start Dialysis — For patients presenting with advanced CKD without prior preparation
Why International Patients Choose Renji Nephrology
- Lupus Nephritis Expertise — Voclosporin triple therapy, obinutuzumab, and CAR-T for refractory LN; seamless integration with Renji's world-class rheumatology department
- IgAN Leadership — Sparsentan, Nefecon, iptacopan, and SGLT2 inhibitors for IgA nephropathy
- Novel Therapy Access — Finerenone, lumasiran, iptacopan, and other novel agents for kidney disease
- Kidney Transplantation — Living and deceased donor transplantation including ABO-incompatible and highly sensitized recipients
- Integrated Rheumatology-Nephrology — Unique strength for autoimmune kidney diseases through Renji's combined rheumatology-nephrology expertise
- Cost-Effectiveness — World-class nephrology care at significantly lower cost than equivalent treatment in Western countries
The CMCS Patient Journey
- Initial Inquiry — Share your kidney disease history, urinalysis, kidney function tests, kidney biopsy reports, autoantibody profile, and current medications with CMCS.
- Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate nephrologist based on your condition — glomerulonephritis, lupus nephritis, diabetic kidney disease, hereditary nephropathy, or kidney transplantation.
- MDT Submission — Where appropriate, we facilitate pre-arrival case review by Renji's nephrology-rheumatology MDT.
- Priority Scheduling — We secure a consultation with minimal waiting time.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near Renji Hospital, and Shanghai airport transfers.
- Diagnostic Support — Full coordination of kidney biopsy, complement studies, genetic testing, and other required investigations.
- Post-Consultation Follow-Up — Biopsy and test result translation, treatment plan interpretation, and remote follow-up coordination after you return home.
Book a Consultation
If you have lupus nephritis, IgA nephropathy, FSGS, ANCA vasculitis, diabetic kidney disease, or end-stage renal disease requiring kidney transplantation — CMCS can arrange a specialist consultation with Renji Hospital's nephrology team in Shanghai.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 則留言